关键词: 创新链, 人才链, 双链融合, 医药成果转化, 产学研协同

Abstract:

 Objective： To address the “Valley of Death” challenge in the transformation of pharmaceutical scientific and technological achievements， this study explores the construction of a transformation model based on the deep integration of the “innovation chain and talent chain.” It analyzes the coupling mechanism and operational logic of this dual-chain model， thereby providing replicable theoretical support and practical paradigms for universities and research institutions.Methods： Drawing upon the reform practices of the State Key Laboratory of Natural and Biomimetic Drugs at Peking University， a closed-loop innovation chain comprising “basic research-application development-collaborative cooperation-achievement incubation and industrialization” and a talent chain characterized by “chain-based matching and capability integration” were constructed. From the perspective of system dynamics， the study analyzed the coupling mechanism of “bidirectional empowerment” between the two chains and investigated the application and effectiveness of each chain in the transformation process.Results： The study indicates that the integration of the two chains has established a spiraling upward mechanism wherein “talent leads innovation， innovation empowers industry， and industry aggregates talent，” effectively facilitating the transfer and transformation of scientific and technological achievements.Conclusion： Through mechanism coupling and risk isolation， the “innovation-talent” dual-chain integration model effectively dismantles barriers in industry-academia-research collaboration， bridging the gap between original innovation and market value. Against the backdrop of the “Healthy China” strategy， this model offers a systematic solution with significant reference value for universities seeking to overcome structural bottlenecks in transformation and drive the high-quality development of the biopharmaceutical industry.

Key words:  , Innovation chain； , Talent chain； , Dual-chain integration； , Pharmaceutical achievement transformation； , Industry-Academia-research collaboration